Closiver Pour-On Solution for Cattle

Main information

  • Trade name:
  • Closiver Pour-On Solution for Cattle
  • Pharmaceutical form:
  • Pour-on solution
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • Closiver Pour-On Solution for Cattle
    Greece
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • ivermectin, combinations
  • Therapeutic area:
  • Cattle

Other information

Status

  • Source:
  • HMA - Europe
  • Authorization number:
  • UK/V/0368/001
  • Authorization date:
  • 23-02-2011
  • EU code:
  • UK/V/0368/001
  • Last update:
  • 09-08-2016

Summary of Product characteristics: dosage,interactions,side effects

Issued:May2011

AN:01861/2009

SUMMARYOFPRODUCTCHARACTERISTICS

1. NameoftheVeterinaryMedicinalProduct

Closiver5mg/ml+200mg/mlPour-OnSolutionforCattle(UK)

ClosamectinVet5mg/ml+200mg/mlPour-OnSolutionforCattle(SE)

Closamectin5mg/ml+200mg/mlPour-OnSolutionforCattle

2. QualitativeandQuantitativeComposition

ActiveIngredient(s)

Ivermectin 5mg/mL

Closantel(asClosantelSodiumDihydrate) 200mg/mL

Excipients

BrilliantBlueFCF(E133) 0.1mg/mL

Forafulllistofexcipientsseesection6.1.

3. PharmaceuticalForm

Pour-Onsolution.

Aclearblue/greensolution.

4. ClinicalParticulars

4.1 TargetSpecies:

Cattle

4.2 IndicationsforUse,SpecifyingtheTargetSpecies:

Forthetreatmentofmixedtrematode(fluke)andnematodeorarthropod

infestationsduetoroundworms,lungworms,eyeworms,warbles,mitesandliceof

cattle.

Trematodes(adultandlateimmatures)

Fasciolagigantica

Fasciolahepatica

Treatmentofflukeat12weeks(mature)>95%efficacy.

Treatmentofflukeat7weeks(lateimmature)>95%efficacy.

Gastrointestinalroundworms(adultsandfourthstagelarvae)

Ostertagiaostertagi(includinginhibitedO.ostertagi),Haemonchusplacei,

Trichostrongylus axei, Trichostrongylus colubriformis, Cooperia spp,

Oesophagostomumradiatum,Nematodirushelvetianus(adult),Strongyloides

papillosus(adult).

Issued:May2011

AN:01861/2009

Lungworms(adultandfourthstagelarvae)

Dictyocaulusviviparus

Eyeworms(adult)

Thelaziaspp

Cattlegrubs(parasiticstages)

Hypodermabovis,Hypodermalineatum

Lice

Linognathusvituli,Haematopinuseurysternus,Damaliniabovis

MangeMites

Chorioptesbovis,Sarcoptesscabieivarbovis

4.3 Contraindications:

Donotuseincasesofknownhypersensitivitytotheactivesubstances.

Donotapplytoareasofskinwhichhavemange,scabsorotherlesionsortoareas

contaminatedwithmudormanure.

DonotusetheproductbetweenDecemberandMarchinthosecountriesinwhich

Hypodermaspphavenotbeeneradicatedaskilledlarvaemaycause

hypersensitivityreactions.

Avermectinsmaynotbewelltoleratedinnon-targetspecies(casesofintolerance

withfataloutcomearereportedindogs –especiallyCollies,OldEnglishSheepdogs

andrelatedbreedsorcrosses,andalsointurtles/tortoises).

4.4 SpecialWarnings:

ThepresenceofliverflukeorHaemonchusinfestationshouldbeconfirmedbefore

thiscombinationproductisused.

Iftreatmentagainstliverflukeinfestationonlyisrequired,asingleactivesubstance

productshouldbeused.

Careshouldbetakentoavoidthefollowingpracticesbecausetheyincreasethe

riskofdevelopmentofresistanceandcouldultimatelyresultinineffectivetherapy.

Toofrequentandrepeateduseofanthelminticsfromthesameclass,overan

extendedperiodoftime.

Underdosing which may be due to underestimation of bodyweight,

misadministrationoftheproduct,orlackofcalibrationofthedosingdevice.

Theeffectofrainonthepour-onformulationatthetimeofandafterapplicationhas

notbeeninvestigated.Formaximumeffectanimalsshouldbekeptindoorsor

undercoverforupto48hoursfollowingtreatment,whenthereisrainoranimminent

riskofrain.

Issued:May2011

AN:01861/2009

Suspectedclinicalcasesofresistancetoanthelminticsshouldbefurther

investigatedusingappropriatetests(e.g.,FaecalEggCountReductionTest).

Wheretheresultsofthetestsstronglysuggestresistancetoaparticular

anthelmintic,ananthelminticbelongingtoanotherpharmacologicalclassand

havingadifferentmodeofactionshouldbeused.

Resistancetoivermectin(anavermectin)hasbeenreportedinCooperiaoncophora

incattlewithintheEU.Thereforetheuseofthisproductshouldbebasedonlocal

(regionalandfarm)epidemiologicalinformationaboutsusceptibilityofthe

gastrointestinalnematodesandrecommendationsonhowtolimitfurtherselection

forresistancetoanthelmintics.

4.5 SpecialPrecautionsforUse:

(i)Specialprecautionsforuseinanimals:

None

(ii)Specialprecautionstobetakenbythepersonadministeringtheveterinary

medicinalproducttoanimals:

Thisproductmaybeirritatingtohumanskinandeyesorcausehypersensitivity.

Avoidskinand/oreyecontactwiththeproductduringtreatment,whenhandling

recentlytreatedanimalsorwhencleaningtheusedequipment.Operators

shouldwearnitrilerubberglovesandbootswithawaterproofcoatwhen

applyingtheproduct.Protectiveclothingshouldbewashedafteruse.If

accidentalskincontactoccurs,washtheaffectedareaimmediatelywithsoap

andwater.Ifaccidentaleyeexposureoccurs,flushtheeyesimmediatelywith

waterandgetmedicalattention.

Thisproductmaybetoxicafteraccidentalingestion.Avoidingestionbyhand-to-

mouthcontact.Donoteat,drinkorsmokewhilsthandlingtheproduct.If

accidentalingestionoccurs,getmedicalattentionandshowthepackageleaflet

tothephysician.Washhandsafteruse.

Thisproductisflammable.Keepawayfromsourcesofignition.Useonlyinwell

ventilatedareasoroutdoors.

(iii)OtherPrecautionsRegardingtheEnvironment.

Theproductisverytoxictoaquaticorganismsanddunginsects.

Treatedcattleshouldnothavedirectaccesstoponds,streamsorditchesfor14

daysaftertreatment.

Longtermeffectsondunginsectscausedbycontinuousorrepeatedusecannotbe

excludedthereforerepeattreatmentsonapasturewithinaseasonshouldonlybe

givenontheadviceofaveterinarian.

Issued:May2011

AN:01861/2009

4.6 AdverseReactions(FrequencyandSeriousness):

Undesirableeffectsarenotexpectedwhentheproductisusedattherecommended

doserate.

4.7 UseDuringPregnancy,LactationorLay:

ClosiverPour-Oncanbeadministeredtocattle(includingdairy,beef/sucklercattle)

atanystageofpregnancyorlactationprovidedthatthemilkisnotintendedfor

humanconsumption.SeeSection4.11.

4.8 InteractionswithOtherMedicinalProductsandOtherFormsofInteraction:

Noneknown.

4.9 AmountstobeAdministeredandAdministrationRoute:

Pour-onuse.

Theveterinarymedicinalproductshouldbeadministeredtopicallyatadosagerate

of500

givermectinperkgbodyweightand20mgclosantelperkgbodyweight(1

mLper10kg).

Theformulationshouldbeappliedalongthemidlineofthebackinanarrowstrip

betweenthewithersandthetailhead.

Toensureadministrationofacorrectdose,bodyweightshouldbedeterminedas

accuratelyaspossible;accuracyofthedosingdeviceshouldbechecked.

Ifanimalsaretobetreatedcollectivelyratherthanindividually,theyshouldbe

groupedaccordingtotheirbodyweightanddosedaccordingly,inordertoavoid

under-oroverdosing.

Thetimingfortreatmentshouldbebasedonlocalepidemiologicalfactorsand

shouldbecustomisedforeachindividualfarm.Acomprehensiveparasitecontrol

programmeshouldbeestablishedbyaveterinaryprofessional.Itshouldbe

confirmedthatmixedinfestationsarepresentbeforetheproductisprescribed.

Theefficacyprofileoftheproductissuchthatasingletreatmentsevenweeksafter

housingwillcontrolinfestationfortheentirehousedperiod.

Theproductshouldnotberepeatedlyapplied(within7weeks)tocattle.

Issued:May2011

AN:01861/2009

4.10Overdose(Symptoms,EmergencyProceduresandAntidotes)(ifnecessary):

Atdosesofthreetimestherecommendeddose,nosignificantclinicalsignswere

recorded.

Ivermectin

Noantidotehasbeenidentified.Symptomatictreatmentmaybebeneficial.

Closantellikeothersalicylanilidesisapotentuncouplerofoxidativephosphorylation

andthesafetyindexisnotashighasisthecaseofmanyotheranthelmintics.

Howeverwhereusedasdirectedthereareunlikelytobeanyuntowardeffects.

Signsofoverdosagecanincludeslightlossofappetite,loosefaeces,decreased

visionandincreasedfrequencyofdefecation.Highdosesmaycauseblindness,

hyperventilation,generalweaknessandinco-ordination,hyperthermia,convulsions,

tachycardiaandinextremecasesdeath.Treatmentofoverdosageissymptomatic

asnoantidotehasbeenidentified.

4.11WithdrawalPeriods:

Meatandoffal:28days

Donotuseincattleproducingmilkforhumanconsumption.

Donotuseinpregnantanimalsintendedtoproducemilkforhumanconsumption.

5. PharmacologicalProperties

ATCVetCode: QP54AA51

PharmacotherapeuticGroup: Ivermectin,combinations.

5.1 PharmacodynamicProperties:

Ivermectinisanendectocidewithactivityagainstawiderangeofinternaland

externalparasites.Ivermectinisamacrocyliclactoneandactsbyinhibitingnerve

impulses.Itbindsselectivelyandwithhighaffinitytoglutamate-gatedchlorideion

channelswhichoccurininvertebratenerveandmusclecells.Thisleadstoan

increaseinthepermeabilityofthecellmembranetochlorideionswith

hyperpolarizationofthenerveormusclecell,resultinginparalysisanddeathofthe

relevantparasites.Compoundsofthisclassmayalsointeractwithotherligand-

gatedchloridechannels,suchasthosegatedbytheneurotransmittergamma-

aminobutyricacid(GABA).Themarginofsafetyforcompoundsofthisclassis

attributabletothefactthatmammalsdonothaveglutamate-gatedchloride

channels.Themacrocyliclactoneshavealowaffinityforothermammalianligand-

gatedchloridechannelsandtheydonotreadilycrosstheblood-brainbarrier.

Closantelisamemberofthesalicylanilideclassofanthelmintics.Salicylanilides

arehydrogen(proton)ionophores(referredtoasoxidativephosphorylase

uncouplers.)

Issued:May2011

AN:01861/2009

Thechemicalstructureofsalicylanilidesillustratethepossessionofadetachable

proton.Thistypeofmoleculeislipophilicandisknowntoshuttleprotonsacross

membranes,inparticulartheinnermitochondrialmembrane.Closantelactsby

uncouplingoxidativephosphorylation.

Closantelisaparasiticidewithflukicideactivityandefficacyagainstcertainother

helminthsandarthropods.

5.2 PharmacokineticProperties:

AftertopicaladministrationofClosiverPour-Ontocattleatadoserateof500µg

ivermectinperkgand20mgclosantelperkgthefollowingparameterswere

observed:Ivermectin –Cmaxof19.13ng/mLandAUCof2440ng.hr/mL;Closantel

–Cmaxof68.5µg/mLandAUCof35207µg.hr/mL.

Ivermectinisonlypartiallymetabolised.Incattle,onlyabout1to2%isexcretedin

theurinetheremainderisexcretedinthefaeces,approximately60%ofwhichis

excretedasunaltereddrug.Theremainderisexcretedasmetabolitesor

degradationproducts.Salicylanilidesarepoorlymetabolisedandareexcreted

mainlyunchanged.About90%ofclosantelisexcretedunchangedinthefaeces

andurineincattle.

6. PharmaceuticalParticulars

6.1 ListofExcipient(s):

BrilliantBlueFCF(E133)Dye

AnhydrousEthanol

Macrogol200

CetearylEthylhexanoate

IsopropylMyristate

PovidoneK30

DenatoniumBenzoate

Trolamine

Isopropylalcohol

6.2 Incompatibilities:

Noneknown.

6.3 Shelf-Life:

Shelf-lifeoftheveterinarymedicinalproductispackagedforsale:1year.

Issued:May2011

AN:01861/2009

6.4 SpecialPrecautionsforStorage:

Donotstoreabove25°C.

Storeuprightinoriginalcontainer.

Protectfromlight.

Discardunusedmaterial.Avoidintroductionofcontamination.

Replacethecapsecurelyafteruse.

Ifstoredattemperaturesbelow0

C,ClosiverPour-OnSolutionforCattlemay

appearcloudy.Allowingtowarmatroomtemperaturewillrestorethenormal

appearancewithoutaffectingefficacy.

Accidentalspillageoringestioncouldbedetrimentalorevenfatalthereforecare

shouldbetakenwhenhandlingandstoringthisproduct.

Flammable –keepawayfromheat,sparks,openflameorothersourcesofignition.

6.5 NatureandCompositionofImmediatePackaging:

Translucent250mLand1LHDPEcontainerswithintegralsqueezemeasurepour

systemandwhiteHDPEcaps.

White1L,2.5Land5LHDPEbackpacksforusewithadosinggundeliverysystem

andwhitepolypropylenescrewcaps.

Notallpackssizesmaybemarketed.

6.6 SpecialPrecautionsfortheDisposalofUnusedVeterinaryMedicinalProduct

orWasteMaterialsDerivedfromtheUseofSuchProducts,ifappropriate:

EXTREMELYDANGEROUSTOFISHANDAQUATICLIFE.Donotcontaminate

surfacewatersorditcheswiththeproductorusedcontainer.Anyunused

veterinarymedicinalproductorwastematerialsderivedfromsuchveterinary

medicinalproductsshouldbedisposedofinaccordancewithlocalrequirements.

Issued:May2011

AN:01861/2009

7. MarketingAuthorisationHolder

NorbrookLaboratoriesLimited

StationWorks

CamloughRoad

Newry

CoDown

BT356JP

NorthernIreland

8. MarketingAuthorisationNumber

Vm02000/4311

9. DateofFirstAuthorisation

19May2011

10. DateofRevisionoftheText

May2011

14-12-2018

Analysis of hunting statistics collection frameworks for wild boar across Europe and proposals for improving the harmonisation of data collection

Analysis of hunting statistics collection frameworks for wild boar across Europe and proposals for improving the harmonisation of data collection

Published on: Thu, 13 Dec 2018 Heterogeneities in the wild boar data collection frameworks across Europe were analysed using questionnaires to explore comparability of hunting data in the short term and propose a common framework for future collection. Fifty‐seven respondents representing 32 countries covering more than 95% of European territory participated to the questionnaire. The most frequently recorded information in the official statistics included the quantity of animals shot per hunting ground ...

Europe - EFSA - European Food Safety Authority Publications

9-11-2011

Danish Pharmacovigilance Update, 20 October 2011

Danish Pharmacovigilance Update, 20 October 2011

In this edition of Danish Pharmacovigilance Update, you can read about: Use of medicines involving a risk of serious and life-threatening skin reactions, the European Medicines Agency to investigate the possible connection between orlistat and rare cases of severe liver toxicity, and the EMA’s review of peritoneal dialysis solutions from Baxter A/S.

Danish Medicines Agency

There are no news related to this product.